breakingview - bristol myer deal gambl pai off twice over
new york (reuter breakingview) - bristol myer squibb ha land two bird in the bush. when the $134 billion u.s. drug firm agre to bui rival oncolog specialist celgen for $74 billion in 2019, it had to divest an autoimmun drug to satisfi regul. instead of keep celgenâ€™s proven blockbust otezla, it sold the drug to amgen for $13.4 billion, keep an unproven candid instead. now a rare head-to-head trial compar the two drug suggest boss giovanni caforio got the better end of on, and possibl two big deal.
